JonesTrading raises target for Praxis Precision Medicines stock
Published on 10/05/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
JonesTrading raised its price target for Praxis Precision Medicines stock from USD 441.00 to USD 534.00 on October 2, 2026, while keeping a Buy rating, according to Moomoo News. The revision gives the clinical-stage biotechnology company a fresh analyst catalyst as its late-stage central nervous system pipeline moves toward regulatory decisions.
Target rises above recent price
The new JonesTrading target stands 14.49 percent above the Nasdaq price of USD 466.42? That comparison is not supported by the available market snapshot, which places PRAX at USD 295.51. Based on the source values, the USD 534.00 target lies 80.71 percent above that price, giving the analyst action a clear numerical context.
Yahoo Finance reports GAAP normalized earnings per share of minus USD 2.87 for the second quarter of 2026 against a consensus estimate of minus USD 3.69. The USD 0.82 difference represents a 22.22 percent earnings surprise, although Praxis still recorded a GAAP net loss of USD 83.72 million for the period.
Pipeline remains the valuation driver
Praxis describes itself as a precision neuroscience company developing therapies for disorders linked to neuronal excitation and inhibition. Its investor-relations page identifies four late-stage product candidates and highlights its Cerebrum small-molecule platform and Solidus antisense oligonucleotide platform, according to Praxis Precision Medicines.
The financial profile remains development-focused: quarterly operating cash flow was negative USD 77.54 million in the second quarter of 2026, while cash and cash equivalents stood at USD 474.76 million at June 30, 2026. Those figures frame the central investment tension around PRAX, with clinical progress carrying the potential to change future revenue prospects while research spending continues to consume cash.
Nasdaq price stays below yearly high
PRAX was last at USD 295.51 on Nasdaq on October 2, 2026, versus a prior close of USD 286.91, a gain of 3.00 percent. The 52-week Nasdaq range was USD 50.31 to USD 392.70, and market capitalization stood at USD 8.2 billion on that date.
Praxis Precision Medicines key data
- Company: Praxis Precision Medicines, Inc.
- ISIN: US74006W2070
- Ticker: PRAX
- Primary exchange: Nasdaq
- Primary exchange price: USD 295.51 on October 2, 2026
- Change versus prior close: plus 3.00 percent
- Prior close: USD 286.91
- Market capitalization: USD 8.2 billion as of October 2, 2026
- 52-week range: USD 50.31-392.70 as of October 2, 2026
- Sector / Industry: Healthcare / Biotechnology
